Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

(2022) Kohei Shitara et al.   NATURE

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

(2021) Yelena Y Janjigian et al.   LANCET

Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma

(2020) Daniel V.T. Catenacci et al.   JOURNAL OF CLINICAL ONCOLOGY

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

(2020) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

(2019) Charles S Fuchs et al.   LANCET ONCOLOGY

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

(2019) Yohann Loriot et al.   NEW ENGLAND JOURNAL OF MEDICINE

FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape

(2019) Samuel J. Klempner et al.   ONCOLOGIST

Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis

(2019) Jinglin Zhang et al.   Cells

Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma

(2019) Steven B. Maron et al.   CLINICAL CANCER RESEARCH

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

(2018) K Muro et al.   ANNALS OF ONCOLOGY

Fibroblast growth factor receptors as treatment targets in clinical oncology

(2018) Masaru Katoh   Nature Reviews Clinical Oncology

FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival

(2016) Soomin Ahn et al.   MODERN PATHOLOGY

Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer

(2015) Nayoung Han et al.   PATHOBIOLOGY

FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study

(2014) X Su et al.   BRITISH JOURNAL OF CANCER

Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma

(2014) Akiko Kawano Nagatsuma et al.   Gastric Cancer

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

(2013) Florian Lordick et al.   LANCET ONCOLOGY

FGFR2 gene amplification and clinicopathological features in gastric cancer

(2012) K Matsumoto et al.   BRITISH JOURNAL OF CANCER